Share-Based Payments

3 Months Ended

Jul. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Payments

Share-Based Payments

The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. The Company also has in place a 2021 Equity Incentive Plan, subject to shareholder approval at its next shareholder meeting. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.

Stock-based compensation expense was recognized as follows (table in thousands):

	Three Months Ended July 31,
	2021		2020
General and administrative	$	171	$	47
Sales and marketing	51		48
Research and development	6		4
Cost of oncology services	52		21
Total stock-based compensation expense	$	280	$	120

Stock Option Grants

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2021 and 2020 were as follows:

	Three Months Ended July 31,
	2021	2020
Expected term in years	6	6
Risk-free interest rates	0.82%	0.39%
Volatility	65.94%-66.21%	72.64%
Dividend yield	—%	—%

The weighted average fair value of stock options granted during the three months ended July 31, 2021 and 2020 was $5.33 and $9.85, respectively.

The Company’s stock options activity for the three months ended July 31, 2021 was as follows:

	Directors and Employees	Non- Employees	Total	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2021	1,618,231	35,415	1,653,646	$	3.96	5.4	$	11,384,000
Granted	82,532	3,000	85,532	9.01		9.90
Exercised	(1,000)	—	(1,000)	2.10
Forfeited	(3,750)	—	(3,750)	10.64
Canceled	—	—	—	—
Expired	—	—	—	—
Outstanding, July 31, 2021	1,696,013	38,415	1,734,428	4.19		5.4	$	11,063,000
Vested and expected to vest as of July 31, 2021	1,696,013	38,415	1,734,428	4.19		5.4	$	11,063,000
Exercisable as of July 31, 2021	1,353,752	9,584	1,363,336	3.50		4.6	$	9,666,000